Robert W. Baird analyst Michael Ulz reiterated a Buy rating on Mersana Therapeutics (NASDAQ:MRSN) Inc on Friday, setting a price target of $30, which is approximately 51.67% above the present share price of $19.78.
Ulz expects Mersana Therapeutics Inc to post earnings per share (EPS) of -$0.33 for the first quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Mersana Therapeutics, with an average price target of $28.
The analysts price targets range from a high of $30 to a low of $26.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $11 thousand and a net profit of -$22.42 million. The company's market cap is $1.35 billion.
According to TipRanks.com, Robert W. Baird analyst Michael Ulz is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.6% and a 51.61% success rate.
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.